UroToday.com· @urotoday · X·· 1 天前评分45
正文 · 原文
ctDNA Tumor Fraction as a Prognostic Biomarker in #TALAPRO3: Talazoparib + Enzalutamide in HRR-mutated #mCSPC. Presented by @AzadOncology @PeterMacCC. #ESMO26 written coverage by @zklaassen_md > https://bit.ly/4zTljYw #ProstateCancer #PrecisionOncology @myESMO
257 浏览 · 3 赞 · 3 转发 · 0 回复
会议摘要
Utility of ctDNA tumor fraction (TF) as a prognostic biomarker in TALAPRO-3: phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA in patients (pts) with homologous recombination repair (HRR) gene–mutated metasta
https://esmocongress.esmo.org来源：UroToday.com · x.com